Protein chip modified by succinyl-beta-cyclodextrin for detecting lyme disease and preparation and application of protein chip
A protein chip, Lyme disease technology, applied in the field of biomedical testing to achieve the effect of improving screening efficiency, positive detection rate and accuracy, reducing non-specificity, and reducing the incidence of false positives and false negatives
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0081] The selection and surface chemical treatment of embodiment 1 carrier
[0082] The present invention selects a gold foil chip from Interactiva Company (Ulm, Germany). Its substrate is a glass sheet covered with a layer of pure gold (purity 99.9%) with a thickness of 10nm. On the gold foil is a regionalized 50μm TEFLON Membrane array (96 holes*2, 8 rows*12 columns), the array aperture is 1.25mm, such as figure 1 shown.
[0083] Step 1. Cleaning of gold foil chips
[0084] Prepare TL1 solution (H 2 O:H 2 o 2 :NH3 ·H 2 O=5:1:1) into a stainless steel box, put the chip into the box, bathe in 82°C water for 5 minutes, rinse with deionized water 4 to 5 times, ethanol twice, each time for 3 minutes; air-dry with nitrogen, dry and store.
[0085] Step 2. Chemically modify the surface of the cleaned gold foil chip to obtain a solid phase carrier
[0086] After cleaning the gold foil chip, immerse it in the aforementioned modification solution 1, and incubate with shaking a...
Embodiment 2
[0089] Embodiment 2 quality control experiment
[0090] Preparation of incubation solution 1: Dissolve VlsE antigen in PBST-BSA solution, and prepare concentration gradients of 0.5μg / ml, 0.25μg / ml, 0.125μg / ml, 0.0625μg / ml, 0.0313μg / ml, 0.0156μg / ml , 0.0078μg / ml, 0.0039μg / ml, 0.0019μg / ml, 0.00095μg / ml, 0.000475μg / ml antigen solution.
[0091] Preparation of incubation solution 2: Dissolve human IgG in PBST-BSA solution, and configure the concentration gradient to be 0.5μg / ml, 0.25μg / ml, 0.125μg / ml, 0.0625μg / ml, 0.0313μg / ml, 0.0156μg / ml, 0.0078μg / ml, 0.0039μg / ml, 0.0019μg / ml, 0.00095μg / ml, 0.000475μg / ml solution;
[0092] Preparation of incubation solution 3: Dissolve Flagellin antigen in PBST-BSA solution, and prepare a concentration gradient of 0.5 μg / ml, 0.25 μg / ml, 0.125 μg / ml, 0.0625 μg / ml, 0.0313 μg / ml, 0.0156 μg / ml, 0.0078μg / ml, 0.0039μg / ml, 0.0019μg / ml, 0.00095μg / ml, 0.000475μg / ml solution;
[0093] Prepare incubation solution 4: dissolve the OspC antigen in PBST-BSA ...
Embodiment 3
[0118] Embodiment 3 repeatability experiment
[0119] Table 1 shows the repeatability experiment within a group. Each 16 wells is regarded as a group, and there are three groups in total. On the same day, the VlsE antigen with a concentration of 0.0156 μg / ml and the rabbit anti-VlsE antigen IgG antibody with a concentration of 50 μg / ml are incubated according to the steps and Cy3-labeled goat anti-rabbit IgG antibody at a concentration of 2.5 μg / ml.
[0120] Table 1
[0121]
[0122] Table 2 shows the repeatability experiment between groups. Each 24 wells is regarded as a group, and there are three groups in total. The VlsE antigen with a concentration of 0.0156 μg / ml and the rabbit anti-VlsE antigen IgG with a concentration of 50 μg / ml were incubated according to the steps within three days. Antibody and Cy3-labeled goat anti-rabbit IgG antibody at a concentration of 2.5 μg / ml.
[0123] Table 2
[0124]
[0125] In Tables 1 and 2, SD is the standard deviation, and CV...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com